A Phase 1 interventional study of atorvastatin and ascorbic acid in Peripheral Arterial Disease, sponsored by Boston University. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-27.
Sponsored by Boston University · Phase 1, Interventional, and Diagnostic
This study will seek to determine whether non-invasive measures of endothelial function have utility as surrogate markers of cardiovascular risk in patients with peripheral arterial disease undergoing vascular surgery. Measurements of endothelial function will be made before and after initiation of atorvastatin, ascorbic acid, or placebo therapy during the pre-operative period. We will then examine cardiovascular events following surgery. We hypothesize that patients who have no improvement in endothelial function will have increased cardiovascular risk compared to patients with improvement in endothelial function.
Part 1 of the study will involve only patients with PAD who are undergoing non-cardiac surgery and is an intervention study. Part 2 will involve patients with PAD who have participated in Part 1 and patients with PAD who are not undergoing surgery. This part of the study does not involve an intervention.
The protocol for patients undergoing surgery is as follows: Part 1. Intervention study with follow-up for 30 days after surgery. Patients with planned surgery will be enrolled. We will test endothelial function at baseline using ultrasound and tonometry. They will then be randomzied to one of three groups: Atorvastatin 80 mg/d, Vitamin C 500 mg/d, or placebo. Subjects already on a statin medication at the time of enrollment will receive 40 mg/d of atorvastatin. Patients taking high dose statin (>40 mg/day) will be randomized to received vitamin C or placebo, and will not be eligible to receive any additional statin as part of the study. In the week immediately prior to surgery, we will test endothelial function a second time. They will then be followed for 30 days beginning with the day of surgery for cardiovascular events. Part 1 of the study involves 4 visits as follows: Visit 1 at enrollment will take place within 7-30 days of non-emergent vascular surgery and will last approximately 60 minutes Visit 2 will take place within approximately 1 week of surgery and will last approximately 30-40 minutes Visit 3 will occur on the 1st post-operative day and will last approximately 10-15 minutes Visit 4 will take place only if the subject is still an in-patient. It will take approximately 10-15 minutes Telephone contact will occur at 30 days post surgery and every six months thereafter for two years. The duration of telephone follow-up is expected to be approximately 5-10 minutes. Part 2 (long term follow-up): Patients who have completed Part 1 will be continued on in Part 2 of the study. Part 2 involves two year follow-up with no study medication. Telephone contact will be made every 6 months. subjects will make a visit to our research unit one year after the initial visit for physical examination, and if applicable, an ultrasound study of their bypass grafts.
The protocol for patients with PAD who are not undergoing surgery is as follows. These patients will participate in Part 2 of the study only (long-term follow-up with no intervention). Visit 1: will last approximately 60 minutes and involve measurement of endothelial function by ultrasound and tonometry. We will contact the subject every 6 months by telephone (5-10 minutes) for two years to determine whether a cardiovascular event has occurred. Visit 2 will occur at 1 year post enrollment and will last approximately 20-30 minutes. If the subject has had peripheral bypass surgery, we will perform an ultrasound study to determine graft blood flow.
1,542 studies on the registry are indexed under Peripheral Arterial Disease; 282 are open to participants now.
This study's enrollment of 108 is above the median of 74 across 1,066 interventional studies indexed under Peripheral Arterial Disease.
Browse Peripheral Arterial Disease studies →Boston University is the lead sponsor of 266 studies on the registry; 37 are open to participants now.
Of its 30 completed or terminated interventional studies of FDA-regulated products, 24 (80%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Atorvastatin 40 or 80 mg/day
Drug: atorvastatin
Ascorbic Acid 500 mg/day
Drug: ascorbic acid
Placebo atorvastatin and Placebo ascorbic acid
Drug: Placebo
atorvastatin 40 or 80 mg/day
Also known as: Lipitor
ascorbic acid 500 mg/day
Also known as: Vitamin C
matching placebo
Change in FMD
Change in flow mediated dilation with treatment: FMD visit 2 - FMD visit 1 FMD is measured by using vascular ultrasound to determine the baseline diameter of the brachial artery. Endothelium-dependent vasodilation is induced by 5-minute arterial occlusion with a blood pressure cuff. When the cuff is released, the resultant increase in blood flow (reactive hyperemia) stimulates vasodilation of the brachial artery. This flow-mediated dilation (FMD) is expressed as the percent change from baseline. Healthy individuals typical dysplay a 10 to 12% dilation. Individuals with PAD had markedly impaired dilation of 6-7. The currernt study sought to determine whether a change in FMD would occur following intervention.
Time frame: 1-4 weeks
Percentage Change in FMD in All Participants With and Without a CVD Event (Not by Treatment Group)
This outcome is independent of the treatment group so the groups are 'CVD event' and ' No CVD Event'. Cardiovascular events (CVD) included cardiovascular disease, myocardial infarction, congestive heart failure, stroke, and unstable angina.
Time frame: 2 months
Recruitment: May 2004 to June 2010.
| Milestone | Atorvastatin | Ascorbic Acid | Placebo |
|---|---|---|---|
| Started | 22 | 44 | 42 |
| Completed | 22 | 44 | 42 |
| Not completed | 0 | 0 | 0 |
Change in flow mediated dilation with treatment: FMD visit 2 - FMD visit 1 FMD is measured by using vascular ultrasound to determine the baseline diameter of the brachial artery. Endothelium-dependent vasodilation is induced by 5-minute arterial occlusion with a blood pressure cuff. When the cuff is released, the resultant increase in blood flow (reactive hyperemia) stimulates vasodilation of the brachial artery. This flow-mediated dilation (FMD) is expressed as the percent change from baseline. Healthy individuals typical dysplay a 10 to 12% dilation. Individuals with PAD had markedly impaired dilation of 6-7. The currernt study sought to determine whether a change in FMD would occur following intervention.
| percent change of FMD | Atorvastatin | Ascorbic Acid | Placebo |
|---|---|---|---|
| Change in FMD | 0.88 ± 3.0 | 0.41 ± 3.6 | 0.88 ± 3.5 |
This outcome is independent of the treatment group so the groups are 'CVD event' and ' No CVD Event'. Cardiovascular events (CVD) included cardiovascular disease, myocardial infarction, congestive heart failure, stroke, and unstable angina.
| percent change of flow-mediated dilation | CVD Event | No CVD Event |
|---|---|---|
| Percentage Change in FMD in All Participants With and Without a CVD Event (Not by Treatment Group) | 0.5 ± 4.0 | 0.7 ± 3.4 |
Collected over 2 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Atorvastatin | 0/22 (0%) | 3/22 (13.6%) | 0/22 (0%) |
| Ascorbic Acid | 1/44 (2.3%) | 6/44 (13.6%) | 0/44 (0%) |
| Placebo | 1/42 (2.4%) | 7/42 (16.7%) | 0/42 (0%) |
| Event | Atorvastatin | Ascorbic Acid | Placebo |
|---|---|---|---|
| Myocardial infactionCardiac disorders | 2/22 | 2/44 | 6/42 |
| CVA/TIANervous system disorders | 2/22 | 2/44 | 0/42 |
| Unstable anginaCardiac disorders | 0/22 | 0/44 | 3/42 |
| Other CVD eventCardiac disorders | 1/22 | 3/44 | 3/42 |
| Congestive heart failureCardiac disorders | 0/22 | 2/44 | 2/42 |
| Venticular fibrillationCardiac disorders | 0/22 | 0/44 | 1/42 |
| Age, Categorical(Participants) | Atorvastatin | Ascorbic Acid | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 11 | 22 | 21 | 54 |
| >=65 years | 11 | 22 | 21 | 54 |
| Age, Continuous(years) | Atorvastatin | Ascorbic Acid | Placebo | Total |
|---|---|---|---|---|
| Mean | 68 ± 11 | 66 ± 8 | 65 ± 9 | 66 ± 9 |
| Sex: Female, Male(Participants) | Atorvastatin | Ascorbic Acid | Placebo | Total |
|---|---|---|---|---|
| Female | 9 | 14 | 6 | 29 |
| Male | 13 | 30 | 36 | 79 |
| Region of Enrollment(participants) | Atorvastatin | Ascorbic Acid | Placebo | Total |
|---|---|---|---|---|
| United States | 22 | 44 | 42 | 108 |
Plan to share: No
No publications or documents are linked to this record.
This study is terminated, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Boston University